Compounds > 3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide
Page last updated: 2024-09-02

3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide and ketamine

3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide has been researched along with ketamine in 1 studies

Compound Research Comparison

Studies
(3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide)		Trials
(3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide)		Recent Studies (post-2010)
(3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide)		Studies
(ketamine)		Trials
(ketamine)		Recent Studies (post-2010) (ketamine)
330403315,0292,3216,678

Protein Interaction Comparison

ProteinTaxonomy3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide (IC50)ketamine (IC50)
Glutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)4.216
Glutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)4.216
Glutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)5.02
Glutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)5.02
Glutamate receptor ionotropic, NMDA 1Homo sapiens (human)3.7762
Glutamate receptor ionotropic, NMDA 2AHomo sapiens (human)3.5563
Glutamate receptor ionotropic, NMDA 2BHomo sapiens (human)4.1059
Glutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)5.02
Glutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)5.02
Glutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)5.02

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Abi-Dargham, A; Carlsson, A; Cooper, TB; Kegeles, LS; Laruelle, M; Mann, JJ; Rodenhiser-Hill, J; Van Heertum, RL; Zea-Ponce, Y1

Trials

1 trial(s) available for 3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide and ketamine

ArticleYear
Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia.
    Biological psychiatry, 2000, Oct-01, Volume: 48, Issue:7

    Topics: Adult; Amphetamine; Benzamides; Corpus Striatum; Dopamine; Dopamine Agents; Dopamine Antagonists; Excitatory Amino Acid Antagonists; Female; Humans; Ketamine; Male; Prefrontal Cortex; Pyrrolidines; Receptors, N-Methyl-D-Aspartate; Schizophrenia; Synaptic Transmission; Tomography, Emission-Computed, Single-Photon

2000